Japan Draws Global Firms Intent On Continuing To Market Off-Patent Drugs
This article was originally published in PharmAsia News
Japan is seen by multinational drug makers as presenting a chance to reverse past tactics and continue building sales for drugs nearing or having reached off-patent status
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.